Oppenheimer & Co. Inc. trimmed its stake in Amgen Inc. by 1.2% in Q1, selling 1,335 shares, bringing its holding to 109,833 ...

Amgen’s first quarter results reflected robust demand across its portfolio, with product volumes and sales increasing in both ...

Amgen plans to proceed with Phase 3 trials, initiating patients on a lower dosage that will gradually increase over an ...

Full Phase 2 study results showed side effects that led people to stop treatment with MariTide, as well as weight loss ...

While Amgen’s monthly obesity candidate MariTide helped patients lose significant amounts of weight in a phase 2 study, ...

Amgen Inc. (NASDAQ:AMGN) is one of the These 10 Stocks Took A Shocking Fall. Amgen Inc. extended its losing streak to a ...

In the most recent trading session, Amgen (AMGN) closed at $280.35, indicating a +1.03% shift from the previous trading day.

Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether ...

Cantor Fitzgerald reaffirmed a neutral rating on Amgen, setting a $305 price target for the medical research firm. Despite ...

Amgen shares are trading lower Monday afternoon. The company released full results from part one of its phase two study of ...

Amgen’s monthly obesity candidate led to substantial weight loss but a high rate of side effects and discontinuations in a ...

Shares of Amgen Inc. AMGN rallied 1.03% to $280.35 Wednesday, on what proved to be an all-around mixed trading session for ...